Search clinical trials for: Semaglutide weekly injection

Total 12984 results

Brigham and Women's Hospital

Completed

Replication of the SEPRA Diabetes Trial in Healthcare Claims Data

Diabetes Mellitus, Type 2

United States
Klaus Gottlob Müller
Novo Nordisk A/S; Independent Research Fund Denmark

Not yet recruiting

Semaglutide in Auto-HSCT (PROTECT)

Inflammation | Chemotherapeutic Toxicity | Intestinal Mucositis
University of Maryland, Baltimore

Recruiting

Pharmacogenetics of Response to GLP1R Agonists (PORT)

Obesity | Diabetes Type 2

United States
Novo Nordisk A/S

Completed

Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis

Obesity

Spain, United States, France, Russian Federation, Canada, Colombia, South Africa, Norway, Denmark, Saudi Arabia, Sweden
Paradigm Biopharmaceuticals USA (INC)

Active, not recruiting

Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium vs Placebo in Participants With Knee OA Pain

Osteoarthritis, Knee

Australia, United States
Novo Nordisk A/S

Completed

Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity

Obesity

Korea, Republic of, Thailand
Yale University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease

Type 2 Diabetes Mellitus | Obesity, Childhood | Impaired Glucose Tolerance | Non-Alcoholic Fatty Liver Disease

United States
University of Nottingham
Medical Research Council

Recruiting

Glucagon-like Peptide-1 Agonism With Very Low Calorie Diets (SemVLCD)

Type 2 Diabetes Mellitus in Obese

United Kingdom
Taipei Veterans General Hospital, Taiwan

Completed

The Effect of Exercise and Cognitive Training on Community-dwelling Older Adults With Dementia.

Dementia | Exercise | Fall | Cognitive Training

Taiwan
University of Colorado, Denver
Novo Nordisk A/S

Recruiting

Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB) (SIB)

Type 2 Diabetes | Chronic Inflammation | Intestinal Permeability

United States
Novo Nordisk A/S

Completed

First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes

Obesity | Diabetes Mellitus, Type 2 | Overweight | Healthy Volunteers

Netherlands
Novo Nordisk A/S

Completed

A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Japan, Hungary, Poland, Russian Federation, Bulgaria, Serbia, Greece, Denmark
Novo Nordisk A/S

Completed

A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Japanese Men

Healthy Volunteers Type 2 Diabetes

Japan
Novo Nordisk A/S

Completed

A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of Semaglutide

Obesity | Overweight | Healthy Volunteers

Germany
Novo Nordisk A/S

Completed

Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes.

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Poland, Slovakia, Czechia
Novo Nordisk A/S

Completed

Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Diabetes Mellitus, Type 2 | Diabetes | Hepatic Impaired

Poland, Slovakia
Virginia Commonwealth University
Novo Nordisk A/S

Recruiting

Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant

NAFLD

United States
Novo Nordisk A/S

Active, not recruiting

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice (PIONEER REAL)

Diabetes Mellitus, Type 2

Spain
Novo Nordisk A/S

Enrolling by invitation

Post-Marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ozempic®

Diabetes Mellitus, Type 2

Japan
Novo Nordisk A/S

Completed

A Research Study Looking at the Comparability (Bioequivalence) of Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity

Obesity | Overweight

Germany
Novo Nordisk A/S

Completed

A Research Study Looking at Similarity Between Once-weekly Semaglutide Versions for Different Injection Pens

Diabetes Mellitus, Type 2 | Healthy Volunteers

Germany
Novo Nordisk A/S

Completed

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Hungary, Czechia
Fundación Instituto de Estudios de Ciencias de...

Not yet recruiting

Effect Of Semaglutide In Coronary Atheroma Plaque (SEPLA)

Atheroscleroses, Coronary
Novo Nordisk A/S

Completed

Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects

Healthy | Diabetes

Netherlands
Novo Nordisk A/S

Completed

Investigating the Pharmacokinetics of Subcutaneous Injections With 1 mg/mL, 3 mg/mL, and 10 mg/mL Semaglutide Strengths and the Absolute Bioavailability of Semaglutide

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing Processes

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations

Non-alcoholic Steatohepatitis

Canada
Yale University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight

Obesity

United States
The Deutsche Diabetes Forschungsgesellschaft e.V.
Novo Nordisk A/S; Boehringer Ingelheim; Federal Ministry of Health, Germany; German... and other collaborators

Recruiting

Combined Active Treatment in Type 2 Diabetes With NASH (COMBAT_T2_NASH)

Type 2 Diabetes | Non-alcoholic Fatty Liver Disease (NAFLD) | Non-alcoholic Steatohepatitis (NASH)

Germany, Austria
Novo Nordisk A/S

Completed

A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Canada, Poland, South Africa, Slovakia
Novo Nordisk A/S

Completed

A Research Trial Looking at the Comparability of 2 Different Concentrations of Semaglutide for the 0.5 Milligram (mg) Dose

Diabetes Mellitus, Type 2 | Healthy Participants

United States
Novo Nordisk A/S

Completed

Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Novo Nordisk A/S

Completed

A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity

Healthy Volunteers Diabetes Mellitus, Type 2 | Healthy Volunteers Overweight | Healthy Volunteers Obesity

Netherlands
Novo Nordisk A/S

Terminated

A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity

Obesity | Overweight

Germany
Novo Nordisk A/S

Completed

A Clinical Trial Looking at the Comparability of 2 Different Forms of Semaglutide

Healthy Volunteers (Diabetes Mellitus, Type 2)

United Kingdom
Geisinger Clinic
Novo Nordisk A/S

Terminated

Treatment of GLP-1 for Diabetic Bariatric Patients (NOVO-GLP1)

Diabetes Mellitus, Type 2

United States
University of Texas Southwestern Medical Center
University of North Carolina, Chapel Hill

Recruiting

DIALYSIS-TIR Study

Type 2 Diabetes | End Stage Renal Disease on Dialysis

United States
University Health Network, Toronto

Recruiting

Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder

Major Depressive Disorder

Canada
Novo Nordisk A/S

Completed

A Research Study to See How Much Semaglutide and SNAC is in the Milk of Healthy, Breastfeeding Women Taking Semaglutide Tablets

Diabetes Mellitus, Type 2

United States
Novo Nordisk A/S

Completed

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (PIONEER REAL)

Diabetes Mellitus, Type 2

Netherlands
Novo Nordisk A/S

Completed

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Sweden, as Part of Local Clinical Practice (PIONEER REAL)

Diabetes Mellitus, Type 2

Sweden
Novo Nordisk A/S

Completed

A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight

Diabetes Mellitus, Type 2

United States, Poland, Puerto Rico, Hungary, Greece
Novo Nordisk A/S

Withdrawn

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice (PIONEER REAL)

Diabetes Mellitus, Type 2
Novo Nordisk A/S

Completed

Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.

Non-alcoholic Steatohepatitis | Hepatobiliary Disorders

United States, Russian Federation, United Kingdom, Denmark, Sweden, Netherlands, Austria, Belgium, Spain, France, Bulgaria, Canada, Australia, Greece, Japan, Finland, Puerto Rico
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus (SUSTAIN 9)

Diabetes Mellitus, Type 2 | Diabetes

United States, Russian Federation, Canada, Austria, Japan, Norway, Puerto Rico
Novo Nordisk A/S

Completed

Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Japan
Shanghai Yinnuo Pharmaceutical Technology Co.,...
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical...

Completed

A Study of the Efficacy and Safety of Supaglutide in Healthy Participants

Diabetes Mellitus, Type 2

China

3

Subscribe